Background: Patients with poor performance status and/or are elderly are frequently
considered a compromised group at high risk of chemotherapy-related morbidities and less …

Increasing interest in designing chemotherapy suitable for use in the elderly and in poor
performance status (PS) patients has led to clinical trials in advanced non-small cell lung …

Elderly patients and younger “unfit” patients with poor Eastern Cooperative Oncology Group
(ECOG) performance status (PS)(≥ 2) suffering from advanced non-small-cell lung cancer …

The aim of the study was to describe in detail the impact of aging and comorbidities on
safety and efficacy of gemcitabine-cisplatin in the subset of elderly with advanced NSCLC …

BACKGROUND. The aim of this study was to compare the efficacy of single‐agent weekly
docetaxel with the combination of docetaxel and gemcitabine in elderly and/or poor …

The purpose of this study was to evaluate the feasibility, toxicity, and efficacy of the
combination of weekly docetaxel and gemcitabine in patients with advanced non–small-cell …

With 69 years being the median age at diagnosis in the United States, management of
elderly patients with advanced non-small cell lung cancer (NSCLC) has become a common …

Background: Vinorelbine prolongs survival and improves quality of life in elderly patients
with advanced non-small-cell lung cancer (NSCLC). Some studies have also suggested that …

BACKGROUND Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high
among elderly patients, few data are available regarding the efficacy and toxicity of …

Background: Following the demonstration that vinorelbine improves survival and quality of
life compared with best supportive care in elderly patients with advanced non-small-cell lung …